Myelodysplastic SyndromesAnemia, RefractoryAnemia, Refractory, with Excess of BlastsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, AcuteSyndromeChromosomes, Human, Pair 5Leukemia, MyeloidAnemia, SideroblasticAzacitidineBone MarrowMyeloproliferative DisordersChromosome AberrationsMonosomyKaryotypingPreleukemiaThalidomideMyelodysplastic-Myeloproliferative DiseasesAnemia, AplasticPancytopeniaChromosomes, Human, Pair 7Cytogenetic AnalysisPrognosisBone Marrow CellsLeukemiaAcute DiseaseChromosome DeletionGranulocyte Precursor CellsTreatment OutcomeNeoplasms, Second PrimaryBone Marrow DiseasesHematopoietic Stem Cell TransplantationIron OverloadAntimetabolites, AntineoplasticTrisomyCytogeneticsErythrocyte TransfusionHematologic AgentsHematopoietic Stem CellsTransplantation, HomologousChelation TherapyAntigens, CD34Survival AnalysisErythropoietinBlood TransfusionCytarabineRemission InductionBlast CrisisTransplantation ConditioningHematopoiesisBone Marrow ExaminationThrombocytopeniaBlood Cell CountVidarabineSurvival RateAnemia, MacrocyticGranulocyte Colony-Stimulating FactorIn Situ Hybridization, FluorescenceHematologic DiseasesDisease ProgressionMutationChromosomes, Human, Pair 8Core Binding Factor Alpha 2 SubunitAntineoplastic AgentsAnemiaSweet SyndromeErythroid Precursor CellsKaryotypeChromosome DisordersHaploinsufficiencyTranslocation, GeneticPrimary MyelofibrosisChromosomes, Human, Pair 20Leukemia, Myelomonocytic, AcuteIron Chelating AgentsHematologic NeoplasmsRetrospective StudiesHematinicsIsochromosomesErythroid CellsFlow CytometryBone Marrow TransplantationErythroblastsDown SyndromeThrombocytosisImmunophenotypingDNA Modification MethylasesHemoglobinuria, ParoxysmalMetabolic Syndrome XAntilymphocyte SerumBusulfanHLA-DR Serological SubtypesMyeloid Progenitor CellsRibonucleoprotein, U2 Small NuclearErythropoiesisRecurrenceFatal OutcomeRisk FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic Combined Chemotherapy Protocols